SGNPDL1V-001

A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors

  • Code NKI: M22PDL
  • Code firma: SGNPDL1V-001
  • Code clinicaltrials.gov: NCT05208762

Principal Investigator

Dr. N. Steeghs

Drugs

SGNPDL1V ADC with MMAE

Summary

This study will test the safety of a drug called SGN-PDL1V in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have three parts. Parts A and B of the study will find out how much SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe SGN-PDL1V is and if it works to treat solid tumor cancers.

Read more on clinicaltrials.gov

Patient population

Tumor type: NSCLC, lung cancer, non small cell lung cancer / HNSCC, Head and Neck Squamous Carcinoma / Esophageal cancer, esophagus carcinoma / Breast cancer, breast carcinoma
Tumor subtype: TNBC, triple negative breast cancer
Tumor characteristics: PDL-1 positive

Additional comments

  • Arm A escalation: HNSCC, NSCLC, THNBC, esophageal SCC – open
  • Arm C: NSCLC (independent of PD-L1 expression) – open
  • Arm C Signal seeking cohort (TNBC, ovarian cancer, esophageal SCC, gastric cancer, or melanoma) – closed yet
  • Arm C: Biology cohort (NSCLC and HNSCC with negative PD-L1 expression, TNBC, esophageal SCC, melanoma, gastric cancer or ovarian cancer) – closed yet